Evidence map›Paper›PMID 42261642›Full record

ArticleActa crystallographica. Section F, Structural biology communications2026

Helical reconstruction of amyloids in cryoSPARC.

Jan Hannes Schaefer, Robert T O'Neill, Joseph P Donnelly, Evan T Powers, Jeffery W Kelly, Gabriel C Lander

Abstract read
In one paragraph

Article in Acta crystallographica. Section F, Structural biology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jan Hannes SchaeferDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, California, USA.
Robert T O'NeillDepartment of Chemistry, Chi-Huey Wong Laboratories for Biomedical Research, Scripps Research Institute, La Jolla, California, USA.ORCID 0000-0002-4348-7635
Joseph P DonnellyDepartment of Chemistry, Chi-Huey Wong Laboratories for Biomedical Research, Scripps Research Institute, La Jolla, California, USA.ORCID 0000-0002-8254-433X
Evan T PowersDepartment of Chemistry, Chi-Huey Wong Laboratories for Biomedical Research, Scripps Research Institute, La Jolla, California, USA.ORCID 0000-0001-8185-8487
Jeffery W KellyDepartment of Chemistry, Chi-Huey Wong Laboratories for Biomedical Research, Scripps Research Institute, La Jolla, California, USA.ORCID 0000-0001-8943-3395
Gabriel C LanderDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, California, USA.ORCID 0000-0003-4921-1135

Funding

IMPACTING MITOCHONDRIAL FUNCTION THROUGH ALTERED PROTEASE ACTIVITYR01NS095892 · NINDS · SCRIPPS RESEARCH INSTITUTE, THE · PI WISEMAN, ROCKLAND LUKE · 2016 to 2025
$5.3M
Deutsche Forschungsgemeinschaft 556478029NIDDK NIH HHS DK046335NINDS NIH HHS NS095892NINDS NIH HHS R01 NS095892
6 · The paper itself

Abstract

Amyloid-mediated proteotoxicity underlies over 50 diseases. Cryo-EM establishes direct links between filament morphologies and pathology, although microbial functional amyloids illustrate that this fold can evolve to serve physiological roles, unlike their pathogenic counterparts. Despite the growing popularity of the processing software cryoSPARC for single-particle analyses, RELION remains the dominant software platform for performing helical reconstruction of amyloid structures, highlighting an area for further development. Here, we present comprehensive processing guidelines for helical reconstruction of helical amyloids using cryoSPARC. Through systematic reprocessing and validation of publicly deposited datasets, we demonstrate the current capabilities and identify the key limitations, emphasizing the need for amyloid-specific parameter optimization within cryoSPARC workflows. Our findings showcase a potential for developing unsupervised processing workflows to meet the demanding throughput requirements of time-resolved in vitro studies and large-scale compound-screening initiatives, thereby accelerating therapeutic drug development. Ultimately, our goal is to shift the focus of amyloid cryo-EM from computationally intensive processing challenges towards addressing fundamental biological questions that enhance our capacity for treatment discovery.

Indexed as

AmyloidCryoelectron MicroscopyImage Processing, Computer-AssistedSoftwareModels, MolecularWorkflowAmyloidamyloidscryo-EMcryoSPARChelical reconstruction

Identifiers

PMID42261642
PMCPMC13335050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.